Supernus Pharmaceuticals Operating Income 2011-2024 | SUPN

Supernus Pharmaceuticals operating income from 2011 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Supernus Pharmaceuticals Operating Income 2011-2024 | SUPN

Supernus Pharmaceuticals operating income from 2011 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$20.1B
Dr Reddy's Laboratories (RDY)$13.1B
BridgeBio Pharma (BBIO)$5B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.4B
Taysha Gene Therapies (TSHA)$449M
Personalis (PSNL)$315M
Assembly Biosciences (ASMB)$117M
Acasti Pharma (ACST)$28M
Sol-Gel Technologies (SLGL)$20M
Evoke Pharma (EVOK)$4M
Teligent (TLGT)$0M